Kodiak Sciences (KOD) Stock Forecast, Price Target & Predictions
KOD Stock Forecast
Kodiak Sciences stock forecast is as follows: an average price target of $32.80 (represents a 1110.33% upside from KOD’s last price of $2.71) and a rating consensus of 'Buy', based on 9 wall street analysts offering a 1-year stock forecast.
KOD Price Target
The average price target for Kodiak Sciences (KOD) is $32.80 based on 1-year price targets from 9 Wall Street analysts in the past 3 months, with a price target range of $114.00 to $8.00. This represents a potential 1110.33% upside from KOD's last price of $2.71.
KOD Analyst Ratings
According to 9 Wall Street analysts, Kodiak Sciences's rating consensus is 'Buy'. The analyst rating breakdown for KOD stock is 0 'Strong Buy' (0.00%), 5 'Buy' (55.56%), 3 'Hold' (33.33%), 1 'Sell' (11.11%), and 0 'Strong Sell' (0.00%).
Kodiak Sciences Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 14, 2022 | - | Morgan Stanley | $9.00 | $7.59 | 18.58% | 232.10% |
| Nov 10, 2022 | - | Goldman Sachs | $8.00 | $7.22 | 10.80% | 195.20% |
| Aug 15, 2022 | - | Morgan Stanley | $12.00 | $11.73 | 2.30% | 342.80% |
| Aug 10, 2022 | - | Chardan Capital | $18.00 | $11.84 | 52.03% | 564.21% |
| Aug 09, 2022 | - | Truist Financial | $15.00 | $11.13 | 34.77% | 453.51% |
| Aug 09, 2022 | - | Goldman Sachs | $9.00 | $11.55 | -22.08% | 232.10% |
| May 24, 2022 | - | Goldman Sachs | $5.00 | $6.55 | -23.66% | 84.50% |
| May 11, 2022 | - | Goldman Sachs | $7.00 | $5.20 | 34.62% | 158.30% |
| Feb 11, 2022 | Andrea Tan | Goldman Sachs | $70.00 | $56.79 | 23.26% | 2483.03% |
| Nov 12, 2021 | Matthew Luchini | BMO Capital | $114.00 | $112.33 | 1.49% | 4106.64% |
The latest Kodiak Sciences stock forecast, released on Nov 14, 2022 by Morgan Stanley company, set a price target of $9.00, which represents a 18.58% increase from the stock price at the time of the forecast ($7.59), and a 232.10% increase from KOD last price ($2.71).
Kodiak Sciences Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $2.71 | $2.71 | $2.71 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Kodiak Sciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Kodiak Sciences's last price of $2.71. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 05, 2024 | H.C. Wainwright | - | Neutral | Initialise |
| Apr 04, 2024 | UBS | Neutral | Neutral | Hold |
| Apr 01, 2024 | Barclays | Underweight | Underweight | Hold |
| Jul 24, 2023 | Raymond James | - | Outperform | Initialise |
| Jul 24, 2023 | Citigroup | Neutral | Overweight | Initialise |
| Jul 24, 2023 | RBC Capital | - | Outperform | Initialise |
| Jul 24, 2023 | Barclays | - | Equal-Weight | Initialise |
| Jul 24, 2023 | Goldman Sachs | Neutral | Buy | Initialise |
| Nov 14, 2022 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
| Aug 15, 2022 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
Kodiak Sciences's last stock rating was published by H.C. Wainwright on Sep 05, 2024. The company Initialise its KOD rating from "null" to "Neutral".
Kodiak Sciences Financial Forecast
Kodiak Sciences Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 20 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | $408.04K | $10.57K |
| High Forecast | - | - | - | - | - | - | - | $489.64K | $12.68K |
| Low Forecast | - | - | - | - | - | - | - | $326.43K | $8.46K |
| # Analysts | - | - | - | - | - | - | - | 16 | 14 |
| Surprise % | - | - | - | - | - | - | - | - | - |
Kodiak Sciences's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. KOD's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Kodiak Sciences EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 20 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 16 | 14 |
| EBITDA | - | - | - | - | - | - | - | $-24.17M | $-7.85M |
| Avg Forecast | - | - | - | - | - | - | - | $-21.07M | $-10.74M |
| High Forecast | - | - | - | - | - | - | - | $-16.86M | $-8.59M |
| Low Forecast | - | - | - | - | - | - | - | $-25.28M | $-12.89M |
| Surprise % | - | - | - | - | - | - | - | 1.15% | 0.73% |
undefined analysts predict KOD's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Kodiak Sciences's previous annual EBITDA (undefined) of $NaN.
Kodiak Sciences Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 20 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 16 | 14 |
| Net Income | - | - | - | - | - | - | - | $-24.39M | $-7.98M |
| Avg Forecast | $-47.14M | $-46.96M | $-46.81M | $-46.70M | $-49.51M | $-47.51M | $-45.80M | $-20.15M | $-10.29M |
| High Forecast | $-47.14M | $-46.96M | $-46.81M | $-46.70M | $-49.51M | $-43.29M | $-45.80M | $-16.12M | $-8.23M |
| Low Forecast | $-47.14M | $-46.96M | $-46.81M | $-46.70M | $-49.51M | $-52.26M | $-45.80M | $-24.18M | $-12.35M |
| Surprise % | - | - | - | - | - | - | - | 1.21% | 0.78% |
Kodiak Sciences's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. KOD's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Kodiak Sciences SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 20 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 16 | 14 |
| SG&A | - | - | - | - | - | - | - | $5.55M | $2.74M |
| Avg Forecast | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - |
Kodiak Sciences's average Quarter SG&A projection for Jun 24 is -, based on 0 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to KOD last annual SG&A of $5.55M (Mar 20).
Kodiak Sciences EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 20 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 16 | 14 |
| EPS | - | - | - | - | - | - | - | $-0.54 | $-0.21 |
| Avg Forecast | $-0.90 | $-0.89 | $-0.89 | $-0.89 | $-0.94 | $-0.90 | $-0.87 | $-0.47 | $-0.37 |
| High Forecast | $-0.90 | $-0.89 | $-0.89 | $-0.89 | $-0.94 | $-0.82 | $-0.87 | $-0.47 | $-0.37 |
| Low Forecast | $-0.90 | $-0.89 | $-0.89 | $-0.89 | $-0.94 | $-0.99 | $-0.87 | $-0.47 | $-0.37 |
| Surprise % | - | - | - | - | - | - | - | 1.16% | 0.57% |
According to undefined Wall Street analysts, Kodiak Sciences's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to KOD previous annual EPS of $NaN (undefined).
Kodiak Sciences Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| KOD | Kodiak Sciences | $2.71 | $32.80 | 1110.33% | Buy |
| CKPT | Checkpoint Therapeutics | $2.30 | $20.00 | 769.57% | Buy |
| RVPH | Reviva Pharmaceuticals | $1.20 | $10.00 | 733.33% | Buy |
| SPRO | Spero Therapeutics | $1.37 | $10.00 | 629.93% | Buy |
| CTMX | CytomX Therapeutics | $1.23 | $5.77 | 369.11% | Buy |
| GOSS | Gossamer Bio | $0.92 | $3.75 | 307.61% | Buy |
| FIXX | Q32 Bio | $0.93 | $2.70 | 190.32% | Buy |
| STOK | Stoke Therapeutics | $14.47 | $33.75 | 133.24% | Buy |
| BMEA | Biomea Fusion | $7.85 | $13.67 | 74.14% | Buy |
| AKRO | Akero Therapeutics | $27.34 | $43.50 | 59.11% | Buy |
| SRPT | Sarepta Therapeutics | $124.65 | $169.93 | 36.33% | Buy |
| MDGL | Madrigal Pharmaceuticals | $241.80 | $315.75 | 30.58% | Buy |
| TIL | Instil Bio | $84.52 | $17.67 | -79.09% | Hold |
KOD Forecast FAQ
Is Kodiak Sciences a good buy?
Yes, according to 9 Wall Street analysts, Kodiak Sciences (KOD) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 55.56% of KOD's total ratings.
What is KOD's price target?
Kodiak Sciences (KOD) average price target is $32.8 with a range of $8 to $114, implying a 1110.33% from its last price of $2.71. The data is based on 9 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Kodiak Sciences stock go up soon?
According to Wall Street analysts' prediction for KOD stock, the company can go up by 1110.33% (from the last price of $2.71 to the average price target of $32.8), up by 4106.64% based on the highest stock price target, and up by 195.20% based on the lowest stock price target.
Can Kodiak Sciences stock reach $4?
KOD's average twelve months analyst stock price target of $32.8 supports the claim that Kodiak Sciences can reach $4 in the near future.
What are Kodiak Sciences's analysts' financial forecasts?
Kodiak Sciences's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-143M (high $-139M, low $-148M), average SG&A $0 (high $0, low $0), and average EPS is $-2.718 (high $-2.637, low $-2.808). KOD's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-188M (high $-188M, low $-188M), average SG&A $0 (high $0, low $0), and average EPS is $-3.57 (high $-3.57, low $-3.57).